Intelligent Bio Solutions reports FY25 EPS ($2.00) vs. ($6.38) last year

Reports FY25 revenue $3.1M vs. $3.1M last year. “Fiscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions (INBS). “We delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we’re focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world’s largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives.”